You are here:

ranolazine (Ranexa)

Advice

following an Independent Review Panel Assessment:

ranolazine (Ranexa®) is not recommended for use within NHS Scotland.

Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).

When added to standard doses of antianginal drugs, ranolazine increased exercise duration at trough drug levels compared with placebo after 12 weeks treatment.  Although significant, the effect size was modest, but not uncommon in studies of patients with stable angina pectoris.

The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by the Independent Review Panel (IRP).

Drug Details

Drug Name: ranolazine (Ranexa)
SMC Drug ID: 565/09
Manufacturer: A Menarini Pharmaceuticals UK Ltd
Indication: As add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
BNF Category:
Sub Category: 2.6 Nitrates calcium-channel blockers and other antianginal drugs
Submission Type: IRP
Status: Not Recommended
Date Advice Published: 12 November 2012

Archived Advice

Resubmission 16 January 2012
Resubmission 13 December 2010
Full submission 7 September 2009

Back